LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

Search

Catalyst Pharmaceuticals Inc

Fermé

SecteurSoins de santé

21.7 -0.32

Résumé

Variation du prix de l'action

24h

Actuel

Min

21.47

Max

22.04

Chiffres clés

By Trading Economics

Revenu

801K

57M

Ventes

-399K

141M

P/E

Moyenne du Secteur

14.319

50.291

BPA

0.68

Marge bénéficiaire

40.119

Employés

181

EBITDA

526K

73M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+53.03% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-287M

2.7B

Ouverture précédente

22.02

Clôture précédente

21.7

Sentiment de l'Actualité

By Acuity

50%

50%

164 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Catalyst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 juin 2025, 21:26 UTC

Principaux Mouvements du Marché

AeroVironment Shares Slide on Stock, Notes Offerings

30 juin 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

BBVA Won't Withdraw Sabadell Offer

30 juin 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30 juin 2025, 23:38 UTC

Market Talk

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30 juin 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

30 juin 2025, 23:03 UTC

Résultats

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30 juin 2025, 22:50 UTC

Acquisitions, Fusions, Rachats

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30 juin 2025, 22:50 UTC

Résultats

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30 juin 2025, 21:26 UTC

Résultats

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30 juin 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 juin 2025, 19:46 UTC

Market Talk

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30 juin 2025, 19:16 UTC

Market Talk

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30 juin 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30 juin 2025, 19:07 UTC

Market Talk

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30 juin 2025, 18:27 UTC

Market Talk

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30 juin 2025, 17:08 UTC

Acquisitions, Fusions, Rachats

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30 juin 2025, 17:00 UTC

Acquisitions, Fusions, Rachats

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30 juin 2025, 16:41 UTC

Market Talk

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30 juin 2025, 16:32 UTC

Market Talk

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30 juin 2025, 16:23 UTC

Acquisitions, Fusions, Rachats

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30 juin 2025, 16:22 UTC

Acquisitions, Fusions, Rachats

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30 juin 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

30 juin 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

30 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 juin 2025, 16:07 UTC

Résultats

Umicore to Post 1H Results on Aug 1

30 juin 2025, 15:59 UTC

Market Talk

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30 juin 2025, 15:55 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30 juin 2025, 15:54 UTC

Market Talk

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30 juin 2025, 15:41 UTC

Acquisitions, Fusions, Rachats

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Comparaison

Variation de prix

Catalyst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

53.03% hausse

Prévisions sur 12 Mois

Moyen 33.33 USD  53.03%

Haut 35 USD

Bas 31 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 24.28Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

164 / 380Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.